

Supplement table 1

**A Systolic blood pressure (SBP) change from baseline by baseline diabetic status**

	Placebo				Empa 10mg				Comparison vs. placebo			interaction p-value
	N	mean (SE)	adjusted mean (SE)	(95% CI)	N	mean (SE)	adjusted mean (SE)	(95% CI)	adjusted mean (SE)	(95% CI)	p-value	
Baseline Diabetic												
Baseline	1446	133.2 (0.4)			1451	133.4 (0.4)						
Week 4	1436	132.2 (0.5)	132.3 (0.4)	(131.6,133.0)	1443	130.6 (0.5)	130.5 (0.4)	(129.8,131.2)	-1.8 (0.5)	(-2.8,-0.8)	0.0005	0.49
Week 12	1399	133.0 (0.5)	133.1 (0.4)	(132.3,133.9)	1392	130.0 (0.5)	130.0 (0.4)	(129.2,130.7)	-3.1 (0.6)	(-4.2,-2.0)	<0.0001	0.11
Week 52	1201	133.3 (0.5)	133.2 (0.5)	(132.3,134.1)	1200	132.2 (0.6)	132.1 (0.5)	(131.2,133.0)	-1.1 (0.6)	(-2.3,0.2)	0.09	0.83
Baseline Non-Diabetic												
Baseline	1500	130.7 (0.4)			1519	130.2 (0.4)						
Week 4	1489	129.9 (0.4)	129.8 (0.4)	(129.1,130.5)	1512	127.4 (0.4)	127.5 (0.4)	(126.8,128.2)	-2.3 (0.5)	(-3.3,-1.3)	<0.0001	0.49
Week 12	1445	128.8 (0.4)	128.6 (0.4)	(127.9,129.4)	1472	126.7 (0.4)	126.8 (0.4)	(126.0,127.5)	-1.9 (0.5)	(-2.9,-0.8)	0.0006	0.11
Week 52	1275	129.7 (0.5)	129.4 (0.4)	(128.5,130.3)	1301	128.3 (0.5)	128.1 (0.4)	(127.3,129.0)	-1.3 (0.6)	(-2.5,-0.1)	0.04	0.83

**B Diastolic blood pressure (DBP) change from baseline by baseline diabetic status**

	Placebo				Empa 10mg				Comparison vs. placebo			interaction p-value
	N	mean (SE)	adjusted mean (SE)	(95% CI)	N	mean (SE)	adjusted mean (SE)	(95% CI)	adjusted mean (SE)	(95% CI)	p-value	
Baseline Diabetic												
Baseline	1446	75.4 (0.3)			1451	75.4 (0.3)						
Week 4	1436	74.4 (0.3)	74.3 (0.2)	(73.9,74.8)	1443	73.5 (0.3)	73.5 (0.2)	(73.0,73.9)	-0.8 (0.3)	(-1.5,-0.2)	0.01	0.72
Week 12	1399	75.1 (0.3)	75.1 (0.2)	(74.6,75.6)	1392	73.5 (0.3)	73.5 (0.2)	(73.0,74.0)	-1.6 (0.3)	(-2.3,-0.9)	<0.0001	0.01
Week 52	1201	75.2 (0.3)	75.2 (0.3)	(74.6,75.7)	1200	74.6 (0.3)	74.6 (0.3)	(74.0,75.1)	-0.6 (0.4)	(-1.4,0.2)	0.13	0.15
Baseline Non-Diabetic												
Baseline	1500	76.1 (0.3)			1519	76.0 (0.3)						
Week 4	1489	75.2 (0.3)	75.2 (0.2)	(74.8,75.7)	1512	74.6 (0.3)	74.6 (0.2)	(74.1,75.0)	-0.7 (0.3)	(-1.3,0.0)	0.04	0.72
Week 12	1445	74.9 (0.3)	74.9 (0.2)	(74.4,75.4)	1472	74.6 (0.3)	74.6 (0.2)	(74.1,75.0)	-0.3 (0.3)	(-1.0,0.3)	0.31	0.01
Week 52	1275	75.0 (0.3)	74.9 (0.3)	(74.3,75.4)	1301	75.1 (0.3)	75.0 (0.3)	(74.5,75.6)	0.2 (0.4)	(-0.6,0.9)	0.64	0.15

Supplement table 2

**A Systolic blood pressure (SBP) change from baseline by baseline LVEF(<50% / ≥50%)**

	Placebo				Empa 10mg				Comparison vs. placebo			interaction p-value
	N	mean (SE)	adjusted mean (SE)	(95% CI)	N	mean (SE)	adjusted mean (SE)	(95% CI)	adjusted mean (SE)	(95% CI)	p-value	
Baseline LVEF < 50%												
Baseline	963	130.6 (0.5)			986	130.5 (0.5)						
Week 4	956	129.6 (0.5)	129.4 (0.4)	(128.5,130.3)	981	127.7 (0.5)	127.7 (0.4)	(126.8,128.5)	-1.7 (0.6)	(-3.0,-0.5)	0.006	0.56
Week 12	918	129.7 (0.6)	129.5 (0.5)	(128.5,130.4)	951	127.0 (0.6)	127.0 (0.5)	(126.1,127.9)	-2.5 (0.7)	(-3.8,-1.2)	0.0002	0.99
Week 52	801	130.7 (0.6)	130.4 (0.6)	(129.3,131.5)	803	129.1 (0.7)	128.7 (0.6)	(127.6,129.8)	-1.7 (0.8)	(-3.2,-0.1)	0.03	0.46
Baseline LVEF ≥ 50%												
Baseline	1983	132.5 (0.4)			1984	132.4 (0.4)						
Week 4	1969	131.7 (0.4)	131.8 (0.3)	(131.2,132.4)	1974	129.6 (0.4)	129.6 (0.3)	(129.0,130.2)	-2.2 (0.4)	(-3.0,-1.3)	<0.0001	0.56
Week 12	1926	131.4 (0.4)	131.5 (0.3)	(130.8,132.1)	1913	128.9 (0.4)	129.0 (0.3)	(128.3,129.6)	-2.5 (0.5)	(-3.4,-1.6)	<0.0001	0.99
Week 52	1675	131.8 (0.5)	131.7 (0.4)	(131.0,132.5)	1698	130.7 (0.4)	130.7 (0.4)	(130.0,131.5)	-1.0 (0.5)	(-2.0,0.1)	0.07	0.46

**B Diastolic blood pressure (DBP) change from baseline by baseline LVEF(<50% / ≥50%)**

	Placebo				Empa 10mg				Comparison vs. placebo			interaction p-value
	N	mean (SE)	adjusted mean (SE)	(95% CI)	N	mean (SE)	adjusted mean (SE)	(95% CI)	adjusted mean (SE)	(95% CI)	p-value	
Baseline LVEF < 50%												
Baseline	963	76.6 (0.3)			986	76.2 (0.3)						
Week 4	956	75.8 (0.3)	75.6 (0.3)	(75.0,76.2)	981	74.4 (0.3)	74.5 (0.3)	(73.9,75.1)	-1.1 (0.4)	(-1.9,-0.3)	0.007	0.32
Week 12	918	76.0 (0.3)	75.8 (0.3)	(75.2,76.4)	951	74.4 (0.4)	74.4 (0.3)	(73.9,75.0)	-1.3 (0.4)	(-2.2,-0.5)	0.001	0.25
Week 52	801	76.5 (0.4)	76.2 (0.3)	(75.5,76.9)	803	75.4 (0.4)	75.4 (0.3)	(74.8,76.1)	-0.8 (0.5)	(-1.7,0.2)	0.12	0.16
Baseline LVEF ≥ 50%												
Baseline	1983	75.3 (0.2)			1984	75.5 (0.2)						
Week 4	1969	74.3 (0.2)	74.4 (0.2)	(74.0,74.8)	1974	73.9 (0.3)	73.8 (0.2)	(73.4,74.2)	-0.6 (0.3)	(-1.2,0.0)	0.04	0.32
Week 12	1926	74.5 (0.2)	74.6 (0.2)	(74.2,75.0)	1913	73.9 (0.3)	73.8 (0.2)	(73.4,74.2)	-0.8 (0.3)	(-1.3,-0.2)	0.01	0.25
Week 52	1675	74.4 (0.3)	74.4 (0.2)	(74.0,74.9)	1698	74.6 (0.3)	74.5 (0.2)	(74.0,75.0)	0.1 (0.3)	(-0.6,0.7)	0.85	0.16